drugset / Trial / NCT03845023

Trial of AD036 in Obstructive Sleep Apnea

NCT03845023

Phase 2 Completed 140 enrolled Apnimed
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double blind, placebo-controlled, repeat-dose, parallel arm, outpatient and inpatient phase 2 clinical study to examine the efficacy and safety of three dose levels of AD036 versus placebo in patients with obstructive sleep apnea.

Timeline

Start
2019-03-07
Primary completion
2019-10-23
Completion
2019-10-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified Oral
Subject Oxybutynin Small molecule Oral